Portfolio company
Rainier Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops targeted antibody therapies for patients with early-stage and metastatic bladder cancer.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
CG Oncology
This biopharmaceutical company develops oncolytic immunotherapies for patients with non-muscle invasive bladder cancer.
Emergence
This biopharmaceutical company develops antibody drug conjugates to treat high-need cancers including bladder and triple-negative breast cancer.
Pionyr Immunotherapeutics
This company develops antibody therapeutics that modify the tumor microenvironment to treat cancer patients.
ArTara Therapeutics
This clinical-stage biopharmaceutical company develops cell therapies and replacement treatments for patients with non-muscle invasive bladder cancer and rare metabolic diseases.
Nectin Therapeutics
This company develops novel immunotherapeutic antibodies and antibody-drug conjugates for patients with solid and haematological cancers.
TORL BioTherapeutics
This biopharmaceutical company develops antibody-drug conjugates and monoclonal antibodies to treat various cancers for patients with unmet medical needs.
Radiant Biotherapeutics
This company develops multi-specific antibody therapies to treat patients with cancer and infectious diseases.
Re-Aim Therapeutics
This early-stage biotechnology company develops antibody-based therapies that target and deplete disease-causing cells to treat patients with autoimmune and inflammatory disorders.